Endocrine Abstracts

Denosumab (DMAB) discontinuation is characterized by an increase in bone turnover and a rapid bone loss. These changes are associated with an increased risk of multiple vertebral fractures (VFx). Prevalent VFx, longer duration of therapy, greater gain in hip BMD during DMAB, and greater loss of hip BMD after DMAB were identified as risk factors for multiple VFx following DMAB cessation in a retrospective analysis of the FREEDOM Extension Study. Case series have indicated that ...